{{Short description|Designer drug}} {{cs1 config|name-list-style=vanc|display-authors=6}} {{Drugbox | IUPAC_name = N-methyl-1-(3-methylphenyl)propan-2-amine | image = 3-Methylmethamphetamine.svg | image_class = skin-invert-image
<!--Clinical data--> | tradename =
<!-- Legal status --> | legal_DE = | legal_UK = | legal_US = Schedule I (isomer of Etilamfetamime)
<!--Identifiers--> | CAS_number = 861007-68-3 | PubChem = 24257262 | ChemSpiderID = 23900070 | UNII_Ref = {{fdacite|correct|FDA}} | UNII = ANT66P7LWF | synonyms = 3-Methyl-''N''-methylamphetamine; 3-MMA; 3MMA; 3-Me-MA; Metaphedrine
<!--Chemical data--> | C=11 | H=17 | N=1 | smiles = CC1=CC(=CC=C1)CC(C)NC | StdInChI = 1S/C11H17N/c1-9-5-4-6-11(7-9)8-10(2)12-3/h4-7,10,12H,8H2,1-3H3 | StdInChIKey = CXVNKBVJDKMLOH-UHFFFAOYSA-N }}
'''Metaphedrine''',<ref>{{Cite web |date=March 4, 2026 |title=Metaphedrine - FDA Global Substance Registration System |url=https://precision.fda.gov/ginas/app/ui/substances/ANT66P7LWF |archive-url=https://web.archive.org/web/20260419052050/https://precision.fda.gov/ginas/app/ui/home |archive-date=April 19, 2026 |access-date=2026-04-19 |website=Food and Drug Administration}}</ref> or '''3-methylmethamphetamine''' ('''3-MMA'''), is a methamphetamine derivative which has been sold as a designer drug, with the substance first encountered online in 2020 and reported in Sweden in 2021.<ref>{{cite book | vauthors = ((European Monitoring Centre for Drugs and Drug Addiction.)) | title = New psychoactive substances: 25 years of early warning and response in Europe. An update from the EU Early Warning System | date = June 2022 | doi = 10.2810/882318 | url = https://www.emcdda.europa.eu/system/files/publications/14637/20222218_PDF_TD0522113ENN_002.pdf | publisher = European Monitoring Centre for Drugs and Drug Addiction | isbn = 978-92-9497-737-3 | doi-broken-date = 12 July 2025 }}</ref><ref name="Aipsin">{{cite web | title=3-MMA (3-Метилметамфетамин) | website=АИПСИН | url=https://aipsin.com/newsubstance/634/ | language=ru | access-date=1 January 2026}}</ref> It is a potent monoamine reuptake inhibitor<ref name="Stalberga_2025">{{cite journal | vauthors = Stalberga D, Kronstrand R, Schranz B, van Zijl N, Karlman S, Aref S, Rautio T, Vikingsson S, Persson M, Gréen H | title = Comprehensive in vitro profiling of traditional and emerging stimulants at monoamine transporters and the 5HT2A receptor. | journal = Authorea | date = 2025 | doi = 10.22541/au.176253891.19158813/v1 }}</ref> and is thought to have psychostimulant effects.<ref name="Aipsin" /> The drug was not active as a serotonin 5-HT<sub>2A</sub> receptor agonist.<ref name="Stalberga_2025" />
== See also == * Substituted amphetamine * 3-Chloromethamphetamine * 3-Methoxymethamphetamine * 3-Methylamphetamine * 3-Methylmethcathinone * 3-Me-PVP * 4-Methylmethamphetamine * Fenfluramine * 3,4-Dimethylamphetamine
== References == {{Reflist}}
==External links== * [https://isomerdesign.com/pihkal/explore/2947 3-Me-MA - Isomer Design]
{{Stimulants}} {{Monoamine releasing agents}} {{Phenethylamines}}
Category:Designer drugs Category:Methamphetamines Category:Methyl compounds Category:Serotonin-norepinephrine-dopamine releasing agents Category:Stimulants
{{Psychoactive-stub}}